Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 16/20 | 0.56 |
| ▸ | HSD11B2 | P80365 | 2/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1264386 | 0.85 | HSD11B1 (0.48) | HSD11B1HSD11B2EPHX2MEN1MAPK1 | |
| SCHEMBL13698839 | 0.85 | MEN1 (0.44) | HSD11B1HSD11B2EPHX2MEN1MAPK1 | |
| SCHEMBL1847058 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL974114 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL974112 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL12578947 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL1847057 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL974113 | 0.82 | HSD11B1 (0.56) | HSD11B1HSD11B2MEN1MAPK1KMT2A | |
| SCHEMBL2444996 | 0.81 | HSD11B1 (0.58) | HSD11B1HSD11B2 | |
| SCHEMBL1844175 | 0.81 | HSD11B1 (0.58) | HSD11B1HSD11B2MEN1MAPK1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115504966-A | Adamantane derivative and application thereof in medicine | 四川海思科制药有限公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-2150526-B1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC (US) | 2017-09-20 | — | — | EP | disclosed |
| US-8907096-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-12-09 | — | — | US | disclosed |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | VTV THERAPEUTICS LLC | 2014-10-23 | — | — | US | disclosed |
| US-8809540-B2 | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2014-08-19 | — | — | US | disclosed |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-09-05 | — | — | US | disclosed |
| US-8383820-B2 | N-adamantyl benzamides as inhibitors of 11-β-hydroxysteroid dehydrogenase | HIGH POINT PHARMACEUTICALS, LLC (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-02-17 | — | — | US | disclosed |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC | 2011-01-06 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC | 2010-03-04 | — | — | US | disclosed |
| EP-2150526-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-02-10 | — | — | EP | disclosed |
| EP-2146952-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2010-01-27 | — | — | EP | disclosed |
| EP-2141990-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | High Point Pharmaceuticals, LLC (US) | 2010-01-13 | — | — | EP | disclosed |
| EP-2125704-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | High Point Pharmaceuticals, LLC (US) | 2009-12-02 | — | — | EP | disclosed |
| WO-2008119017-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-10-02 | — | — | WO | disclosed |
| WO-2008101886-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101885-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (US) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008101914-A2 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HIGH POINT PHARMACEUTICALS, LLC (GB) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003856-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885HSD11B2 4/4885EPHX2 1278/4885 |
| US-20110039853-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885HSD11B2 4/4885EPHX2 1278/4885 |
| US-20100056600-A1 | 11BETA-HSD1 ACTIVE COMPOUNDS | HSD11B1, HSD3B1, HSD11B2 | HSD11B1 1/4885HSD11B2 3/4885EPHX2 1756/4885 |
| US-20110003852-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885HSD11B2 4/4885EPHX2 1278/4885 |
| US-20130231341-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885HSD11B2 4/4885EPHX2 1278/4885 |
| US-20140315905-A1 | N-ADAMANTYL BENZAMIDES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE | HSD11B1, HSD3B1, HSD17B1 | HSD11B1 1/4885HSD11B2 4/4885EPHX2 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.